SLC5A2 and chronic kidney disease: SGLT-2 inhibitors were associated with a lower incidence of the composite renal outcome in patients with CKD, compared with placebo: RR 0.77 (95% CI 0.68–0.88; P < 0.001) (Fig. 4 and Table 3).